Enhancement of cytochrome P-450 3A4 catalytic activities by cytochrome b5 in bacterial membranes

Drug Metabolism and Disposition

Volumn 27, Issue 9, 1999, Pages 999-1004

  Yamazaki, Hiroshi ^a   Nakajima, Miki ^a   Nakamura, Mami ^a   Asahi, Satoru ^b   Shimada, Noriaki ^c   Gillam, Elizabeth M J ^d   Guengerich, F Peter ^e   Shimada, Tsutomu ^f   Yokoi, Tsuyoshi ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

^c DAIICHI PURE CHEMICALS CO LTD   (Japan)

^d UNIVERSITY OF QUEENSLAND   (Australia)

^e VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f OSAKA PREFECTURAL INSTITUTE OF PUBLIC HEALTH   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; CYTOCHROME B5; CYTOCHROME P450; MIDAZOLAM; NIFEDIPINE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE FERRIHEMOPROTEIN REDUCTASE; TESTOSTERONE;

ANIMAL CELL; ARTICLE; BACTERIAL MEMBRANE; CATALYSIS; CONTROLLED STUDY; DRUG OXIDATION; ESCHERICHIA COLI; HUMAN; HUMAN CELL; HYDROXYLATION; LIVER MICROSOME; NONHUMAN; PRIORITY JOURNAL;

ANESTHETICS, INTRAVENOUS; BACTERIA; CALCIUM CHANNEL BLOCKERS; CYTOCHROME P-450 ENZYME SYSTEM; CYTOCHROMES B5; ESCHERICHIA COLI; HUMANS; HYDROXYLATION; KINETICS; MEMBRANES; MIDAZOLAM; MIXED FUNCTION OXYGENASES; NADPH-FERRIHEMOPROTEIN REDUCTASE; NIFEDIPINE; OXIDATION-REDUCTION; RECOMBINANT PROTEINS; TESTOSTERONE;

ANIMALIA; BACTERIA (MICROORGANISMS); ESCHERICHIA COLI; INSECTA;

EID: 0032821946     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Brian WR, Sari MA, Iwasaki M, Shimada T, Kaminsky LS and Guengerich FP (1990) Catalytic activities of human liver cytochrome P-450IIIA4 expressed in Saccharomyces cerevisiae. Biochemistry 29:11280-11292.
2. Buters J, Korzekwa KR, Kunze KL, Omata Y, Hardwick JP and Gonzalez FJ (1994) cDNA-directed expression of human cytochrome P450 CYP3A4 using baculovirus. Drug Metab Dispos 22:688-692.
3. Crespi CL (1995) Xenobiotic-metabolizing human cells as tools for pharmacological and toxicological research. Adv Drug Res 26:179-235.
4. Dong M-S, Yamazaki H, Quo Z and Guengerich FP (1996) Recombinant human cytochrome P450 1A2 and N-terminal-truncated form: Construction, purification, aggregation properties, and interactions with flavodoxin, ferredoxin, and NADPH-cytochrome P450 reductase. Arch Biochem Biophys 327:11-19.
5. Gillam E, Baba T, Kim B-R, Ohmori S and Guengerich FP (1993) Expression of modified human cytochrome P450 3A4 in Escherichia coli and purification and reconstitution of the enzyme. Arch Biochem Biophys 305:123-131.
6. Gonzalez FJ, Crespi CL and Gelboin HV (1991) cDNA-expressed human cytochrome P450s: A new age of molecular toxicology and human risk assessment. Mutat Res 247:113-127.
7. Gonzalez FJ and Gelboin HV (1994) Role of human cytochromes P450 in the metabolic activation of chemical carcinogens and toxins. Drug Metab Rev 26:165-183.
8. Guengerich FP (1994) Analysis and characterization of enzymes, in Principles and Methods of Toxicology (Hayes AW ed) pp 1259-1313, Raven Press, New York.
9. Guengerich FP (1995) Human cytochrome P450 enzymes, in Cytochrome P450 (Oritiz de Montellano PR ed) pp 473-535, Plenum Press, New York.
10. Guengerich FP, Martin MV, Guo Z and Chun Y-J (1996) Purification of functional recombinant P450s from bacteria. Methods Enzymol 272:35-44.
11. Guengerich FP and Shimada T (1991) Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes. Chem Res Toxicol 4:391-407.
12. Guengerich FP, Wang P and Davidson NK (1982) Estimation of isozymes of microsomal cytochrome P-450 in rats, rabbits, and humans using immunochemical staining coupled with sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Biochemistry 21:1698-1706.
13. Guengerich FP, Wang P and Mason PS (1981) Immunological comparison of rat, rabbit, and human liver NADPH-cytochrome P-450 reductase. Biochemistry 20:2379-2385.
14. Imaoka S, Yamada T, Hiroi T, Hayashi K, Sakai T, Yabusaki Y and Funae Y (1996) Multiple forms of human P450 expressed in Saccharomyces cerevisiae. Systematic characterization and comparison with those of the rat. Biochem Pharmacol 51:1041-1050.
15. Inoue K, Yamazaki H, Imiya K, Akasaka S, Guengerich FP and Shimada T (1997) Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4′-hydroxylation activities in livers of Japanese and Caucasian populations. Pharmacogenetics 7:103-113.
16. Ito K, Iwatsubo T, Kanamitsu S, Nakajima Y and Sugiyama Y (1998) Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport. Annu Rev Pharmacol Toxicol 38:461-499.
17. Iwatsubo T, Hirota N, Ooie T, Suzuki H, Shimada N, Chiba K, Ishizaki T, Green CE, Tyson CA and Sugiyama Y (1997) Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacol Ther 73:147-171.
18. Kobayashi K, Chiba K, Yagi T, Shimada N, Taniguchi T, Horie T, Tani M, Yamamoto T, Ishizaki T and Kuroiwa Y (1997) Identification of cytochrome P450 isoforms involved in citalopram N-demethylation by human liver microsomes. J Pharmacol Exp Ther 280:927-933.
19. Kronbach T, Mathys D, Umeno M, Gonzalez FJ and Meyer UA (1989) Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol Pharmacol 36:89-96.
20. Lee CA, Kadwell SH, Kost TA and Serbjit-Singh CJ (1995) CYP3A4 expressed by insect cells infected with a recombinant baculovirus containing both CYP3A4 and human NADPH-cytochrome P450 reductase is catalytically similar to human liver microsomal CYP3A4. Arch Biochem Biophys 319:157-167.
21. Li AP, Maurel P, Gomez-Lechon MJ, Cheng LC and Jurima-Romet M (1997) Preclinical evaluation of drug-drug interaction potential: Present status of the application of primary human hepatocytes in the evaluation of cytochrome P450 induction. Chem Biol Interact 107:5-16.
22. Lowry OH, Rosebrough NJ, Farr AL and Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275.
23. Mäenpää J, Hall SD, Ring BJ, Strom SC and Wrighton SA (1998) Human cytochrome P450 3A (CYP3A) mediated midazolam metabolism: The effect of assay conditions and regioselective stimulation by α-naphthoflavone, terfenadine and testosterone. Pharmacogenetics 8:137-155.
24. Nakajima M, Kobayashi K, Shimada N, Tokudome S, Yamamoto T and Kuroiwa Y (1998) Involvement of CYP1A2 in mexiletine metabolism. Br J Clin Pharmacol 44:55-62.
25. Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, Waterman MR, Gotoh O, Coon MJ, Estabrook RW, Gunsalus IC and Nebert DW (1996) P450 superfamily: Update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 6:1-42.
26. Omura T and Sato R (1964) The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J Biol Chem 239:2370-2378.
27. Parikh A, Gillam EMJ and Guengerich FP (1997) Bacterial catalysis of reactions important in mammalian drug and xenobiotic metabolism: Functional co-expression of six human microsomal cytochrome P450 enzymes with NADPH-cytochrome P450 reductase in Escherichia coli. Nat Biotechnol 15:784-788.
28. Renaud JP, Peyronneau MA, Urban P, Truan G, Cullin C, Pompon D, Beaune P and Mansuy D (1993) Recombinant yeast in drug metabolism. Toxicology 82:39-52.
29. 5. Arch Biochem Biophys 348:107-115.
30. Shimada T, Misono KS and Guengerich FP (1986) Human liver microsomal cytochrome P-450 mephenytoin 4-hydroxylase, a prototype of genetic polymorphism in oxidative drug metabolism. Purification and characterization of two similar forms involved in the reaction. J Biol Chem 261:909-921.
31. Shimada T, Wunsch RM, Hanna IH, Sutter TR, Guengerich FP and Gillam EMJ (1998) Recombinant human cytochrome P450 1B1 expression in Escherichia coli. Arch Biochem Biophys 351:111-120.
32. Shimada T and Yamazaki H (1998) Cytochrome P450 reconstitution systems, in Methods in Molecular Biology (Phillips IR and Shephard EA eds) pp 85-93, Humana Press, Totowa, NJ.
33. Shimada T, Yamazaki H. Mimura M, Inui Y and Guengerich FP (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414-423.
34. 5. Methods Enzymol 52:97-101.
35. Venkatakrishnan K, von Moltke LL and Greenblatt DJ (1998) Relative quantities of catalytically active CYP 2C9 and 2C19 in human liver microsomes: Application of the relative activity factor approach. J Pharm Sci 87:845-853.
36. Wilkinson GR (1996) Cytochrome P4503A (CYP3A) metabolism: Prediction of in vivo activity in humans. J Pharmacokin Biopharm 24:475-490.
37. Williams CH Jr and Kamin H (1962) Microsomal triphosphopyridine nucleotide-cytochrome c reductase of liver. J Biol Chem 237:587-595.
38. Wrighton SA and Stevens JC (1992) The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol 22:1-21.
39. 5 interactions. Arch Biochem Biophys 342:329-337.
40. Yamazaki H, Inoue K, Shaw PM, Checovich WJ, Guengerich FP and Shimada T (1997b) Different contributions of cytochrome P450 2C19 and 3A4 in the oxidation of omeprazole by human liver microsomes: Effects of contents of these two forms in individual human samples. J Pharmacol Exp Ther 283:434-442.
41. 5. J Biol Chem 271:27438-27444.
42. 5 in the oxidation of testosterone and nifedipine by recombinant cytochrome P450 3A4 and by human liver microsomes. Arch Biochem Biophys 325:174-182.
43. Yasukochi Y and Masters BSS (1976) Some properties of a detergent-solubilized NADPH-cytochrome c (cytochrome P-450) reductase purified by biospecific affinity chromatography. J Biol Chem 251:5337-5344.